• Anticancer drugs
Page 
 of 9
Records 101 to 120 of 168
 
Genomics of Drug Sensitivity in Cancer
Targets
Target pathway
Download molecule
Cluster number
calculated LogS
Molecular weight
calculated LogP
Ro5 violations
Epothilone B Microtubule stabiliser Mitosis 448013 129 -4,686 507,69 4,4793 1
BMS-345541 IKK1, IKK2 Other, kinases 9813758 101 -4,664 255,324 0,8626 0
GW-2580 CSF1R RTK signaling 11617559 69 -4,648 366,42 2,4867 0
JNK Inhibitor VIII JNK JNK and p38 signaling 11624601 68 -4,551 356,381 1,8617 0
Palbociclib CDK4, CDK6 Cell cycle 5330286 114 -4,534 447,541 2,003 0
Motesanib VEGFR, RET, KIT, PDGFR RTK signaling 11667893 63 -4,512 373,459 2,3483 0
Doxorubicin Anthracycline DNA replication 31703 147 -4,507 543,523 0,1673 3
Pictilisib PI3K (class 1) PI3K/MTOR signaling 17755052 7 -4,488 513,645 1,3339 1
Rucaparib PARP1, PARP2 Genome integrity 9931953 95 -4,463 323,37 2,5426 0
Olaparib PARP1, PARP2 Genome integrity 23725625 6 -4,454 434,47 3,1669 0
SB-505124 ALK4, ALK5 RTK signaling 9858940 92 -4,407 335,406 4,391 0
Imatinib ABL, KIT, PDGFR RTK signaling 5291 90 -4,383 493,613 3,9383 0
QS11 ARFGAP1 Other 4263900 120 -4,363 419,864 1,1479 0
CCT007093 PPM1D Other 2314623 123 -4,34 272,391 4,2292 0
S-Trityl-L-cysteine KIF11 Mitosis 76044 143 -4,265 363,48 1,4958 0
PIK-93 PI3Kgamma PI3K/MTOR signaling 6852167 107 -4,248 389,883 2,4958 0
SB590885 BRAF ERK MAPK signaling 11316960 78 -4,217 453,544 1,9842 0
Ponatinib ABL, PDGFRA, VEGFR2, FGFR1, SRC, TIE2, FLT3 RTK signaling 24826799 22 -4,215 532,568 3,8413 1
Entinostat HDAC1, HDAC3 Chromatin histone acetylation 4261 151 -4,205 376,415 2,1633 0
AR-42 HDAC1 Chromatin histone acetylation 6918848 104 -4,179 312,368 2,8761 0
Page 
 of 9
Records 101 to 120 of 168
Information useful only for research purposes.